Draft scoping review: melanocortin receptor agonists — disposition

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

§3.3Resulting amendments

1. The same concern is used to downgrade in two domains — arising from DRAFT-MELANOCORTIN/001. The rating for the first outcome has been raised by one level and the domain reasoning restated, and the reasoning for the second has been rewritten to make clear that the two downgrades rest on different features of the evidence.
2. The axis of the forest plot exaggerates a small difference — arising from DRAFT-MELANOCORTIN/002. Forest plots now carry a marked minimally important difference wherever a published one exists for the outcome, with its source cited. Where none exists the figure says so beneath the axis.
3. The review does not say when it will be updated or what would trigger an update — arising from DRAFT-MELANOCORTIN/003. Every synthesis now records a scheduled review date and a stated update trigger, being the reporting of a trial that would materially change the contributing evidence, and the registered trials capable of triggering an update are listed by name.
4. A funnel plot is presented for a set too small to interpret it — arising from DRAFT-MELANOCORTIN/004. The funnel plot is removed for every outcome contributed by fewer than ten studies, and replaced by a statement that small-study effects could not be assessed at that number, together with the count of registered trials identified without posted results.
5. The comparator was given at a dose below the one in general use — arising from DRAFT-MELANOCORTIN/006. Comparator dose is now a column in the included-studies table, and a sensitivity analysis restricted to comparators at the dose in general use is reported wherever the trials permit it.
6. Efficacy outcomes are rated for certainty and harms are not — arising from DRAFT-MELANOCORTIN/007. Every reported harm now carries a certainty rating on the same scale as the efficacy outcomes, with the downgrade reasons stated, and discontinuation for adverse events appears in the summary of findings rather than in an annex.
7. References should carry a persistent identifier for every cited source — arising from DRAFT-MELANOCORTIN/009. Every reference without a persistent identifier now carries an explicit statement that the identifier is not held by the Institute, so that its absence is a recorded fact rather than an apparent oversight.
8. Analytical surveys are treated as evidence about suppliers when they establish only what was in a… — arising from DRAFT-MELANOCORTIN/010. Provenance is now assessed for every included survey and reported as a study characteristic, surveys without establishable provenance are reported separately rather than pooled with those that have it, and no supplier-level inference is drawn from a…
9. An indirect comparison is presented without an assessment of transitivity — arising from DRAFT-MELANOCORTIN/011. Transitivity is now assessed against a stated list of effect modifiers and reported before any indirect estimate, and where the assessment fails the contrast is reported as unestimable with the reason rather than estimated with a caveat.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.